Skip to content

An exploratory study and safety evaluation of minimally invasive complete prostatectomy in patients with clinically advanced benign prostatic hyperplasia and high risk of prostate cancer

An exploratory study and safety evaluation of minimally invasive complete prostatectomy in patients with clinically advanced benign prostatic hyperplasia and high risk of prostate cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072014
Enrollment
Unknown
Registered
2023-05-31
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostate Hyperplasia

Interventions

Arm 1:Complete Prostatectomy (Laparoscopic/Robot-Assisted Laparoscopic)
Arm 2:Transurethral resection of the prostate (plasma or laser ablation)

Sponsors

Department of Urology, Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 45 years = age = 75 years 2. Patients must meet both of the following two categories of conditions: 1)Diagnosed with benign prostatic hyperplasia, and the disease severity has met any two of the following surgical indications (according to the “Chinese Urology and Andrology Disease Diagnosis and Treatment Guidelines (2019 Edition)”): a) Recurrent hematuria b) History of acute urinary retention c) IPSS score = 20 points d) Residual urine volume = 50ml e) Maximum urinary flow rate = 4 points iii) Have undergone BRCA1/2 mutation gene testing and indicated mutation. 3. Patients who voluntarily participate and sign the informed consent form, and can cooperate to complete the entire trial process

Exclusion criteria

Exclusion criteria: 1)With severe infectious diseases such as bacteremia and sepsis. 2)Severe coagulation dysfunction. 3)Patients with severe heart, brain, lung, liver, kidney and other diseases who cannot tolerate surgery. 4)Patients with other malignant tumors. 5)Patients who clearly express concerns about postoperative side effects such as urinary incontinence and erectile dysfunction 6)Concomitant use of prohibited drugs, including systemic anti-tumor drugs and immunosuppressants. 7)Participated in other clinical trials within the last 3 months. 8)Other situations that the researcher considers inappropriate to participate in this clinical trial. 9)Patients with fertility and sexual life requirements

Design outcomes

Primary

MeasureTime frame
International Prostate Symptom Score;peak of urine flow rate;Postvoid Residual;

Secondary

MeasureTime frame
Malignant tumor;Diagnosis of prostate cancer;Postoperative adverse events;

Countries

China

Contacts

Public ContactHaowen Jiang

Huashan Hospital Affiliated to Fudan University

urology_hs@163.com+86 181 2118 6785

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026